Armata Total Current Liabilities from 2010 to 2025
| ARMP Stock | USD 2.08 0.09 4.15% |
Total Current Liabilities | First Reported 1993-12-31 | Previous Quarter 123.2 M | Current Value 118.2 M | Quarterly Volatility 19.7 M |
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 10 M, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
Armata | Total Current Liabilities |
Latest Armata Pharmaceuticals' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Armata Pharmaceuticals over the last few years. Total Current Liabilities is an item on Armata Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Armata Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Armata Pharmaceuticals' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Armata Total Current Liabilities Regression Statistics
| Arithmetic Mean | 7,469,925 | |
| Geometric Mean | 4,556,937 | |
| Coefficient Of Variation | 104.78 | |
| Mean Deviation | 6,282,638 | |
| Median | 4,814,000 | |
| Standard Deviation | 7,827,246 | |
| Sample Variance | 61.3T | |
| Range | 24M | |
| R-Value | 0.78 | |
| Mean Square Error | 25.3T | |
| R-Squared | 0.62 | |
| Significance | 0.0003 | |
| Slope | 1,289,544 | |
| Total Sum of Squares | 919T |
Armata Total Current Liabilities History
About Armata Pharmaceuticals Financial Statements
Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 18.9 M | 19.9 M |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.